The spike protein of SARS-CoV-2 variant A. 30 is heavily mutated and evades vaccine-induced antibodies with high efficiency

P Arora, C Rocha, A Kempf, I Nehlmeier… - Cellular & molecular …, 2021 - nature.com
The COVID-19 pandemic, caused by SARS-CoV-2, continues to rage in many countries,
straining health systems and economies. Vaccines protect against severe disease and …

Insights into SARS-CoV-2's mutations for evading human antibodies: sacrifice and survival

B Luan, T Huynh - Journal of medicinal chemistry, 2021 - ACS Publications
The highly infectious SARS-CoV-2 variant B. 1.351 that first emerged in South Africa with
triple mutations (N501Y, K417N, and E484K) is globally worrisome. It is known that N501Y …

A non-ACE2-blocking neutralizing antibody against Omicron-included SARS-CoV-2 variants

X Duan, R Shi, P Liu, Q Huang, F Wang… - … and Targeted Therapy, 2022 - nature.com
The emergence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) variants
threatens efforts to contain the coronavirus disease 2019 (COVID-19) pandemic. Omicron …

Omicron: a heavily mutated SARS-CoV-2 variant exhibits stronger binding to ACE2 and potently escapes approved COVID-19 therapeutic antibodies

M Shah, HG Woo - Frontiers in immunology, 2022 - frontiersin.org
The new SARS-CoV-2 variant of concern “Omicron” was recently spotted in South Africa and
spread quickly around the world due to its enhanced transmissibility. The variant became …

[HTML][HTML] Increased resistance of SARS-CoV-2 variant P. 1 to antibody neutralization

P Wang, RG Casner, MS Nair, M Wang, J Yu… - Cell host & …, 2021 - cell.com
The emergence of SARS-CoV-2 variants has raised concerns about altered sensitivity to
antibody-mediated immunity. The relative resistance of SARS-CoV-2 variants B. 1.1. 7 and …

The alpha/B. 1.1. 7 SARS-CoV-2 variant exhibits significantly higher affinity for ACE-2 and requires lower inoculation doses to cause disease in K18-hACE2 mice

R Bayarri-Olmos, LB Johnsen, M Idorn, LS Reinert… - Elife, 2021 - elifesciences.org
The alpha/B. 1.1. 7 SARS-CoV-2 lineage emerged in autumn 2020 in the United Kingdom
and transmitted rapidly until winter 2021 when it was responsible for most new COVID-19 …

Broad ultra-potent neutralization of SARS-CoV-2 variants by monoclonal antibodies specific to the tip of RBD

H Ma, Y Guo, H Tang, CTK Tseng, L Wang, H Zong… - Cell Discovery, 2022 - nature.com
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs)
continue to wreak havoc across the globe. Higher transmissibility and immunologic …

Structural basis for accommodation of emerging B. 1.351 and B. 1.1. 7 variants by two potent SARS-CoV-2 neutralizing antibodies

G Cerutti, M Rapp, Y Guo, F Bahna, J Bimela… - Structure, 2021 - cell.com
Summary Emerging SARS-CoV-2 strains, B. 1.1. 7 and B. 1.351, from the UK and South
Africa, respectively, show decreased neutralization by monoclonal antibodies and …

Evidence of escape of SARS-CoV-2 variant B. 1.351 from natural and vaccine-induced sera

D Zhou, W Dejnirattisai, P Supasa, C Liu, AJ Mentzer… - Cell, 2021 - cell.com
The race to produce vaccines against severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) began when the first sequence was published, and this forms the basis for …

Impact of the N501Y substitution of SARS-CoV-2 Spike on neutralizing monoclonal antibodies targeting diverse epitopes

L Cheng, S Song, B Zhou, X Ge, J Yu, M Zhang, B Ju… - Virology journal, 2021 - Springer
The emergence and rapid spread of the B. 1.1. 7 lineage (VOC-202012/01) SARS-CoV-2
variant has aroused global concern. The N501Y substitution is the only mutation in the …